SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Ambys Medicines, a cell and gene therapy company focused on advancing novel treatments to restore and regenerate liver function, today announced the appointment of Ronald Park, M.D., as the company’s new Chief Executive Officer. Dr. Park also joins the Ambys board of directors.

Dr. Park is a highly regarded life sciences executive with broad executive leadership experience and a successful track record of driving results in pioneering fields and innovative situations. Prior to Ambys, he was EVP and General Manager for Health and DNA at Ancestry and held multiple roles at Roche and Genentech over a 17-year career, including co-Global Head and VP for Roche’s Personalized Healthcare (PHC) Center of Excellence, General Manager for Denmark and Iceland, and Global Lifecycle Leader for Actemra. Earlier in his career, Dr. Park worked for McKinsey & Company and was on the faculty of UCLA as Assistant Professor of Internal Medicine. Throughout his 20-year career in the life sciences, he has worked in functional roles that have spanned the entire product lifecycle and on products that have achieved blockbuster status across multiple therapeutic areas. Dr. Park has also served on Boards for cell and gene therapy companies and consumer digital wellness. Dr. Park received his M.D. and M.B.A. from Stanford University and a B.A. with honors in Biology from Harvard.

“We are excited to have found in Ron the ideal candidate to lead Ambys as CEO at this important time. Ambys has made significant progress over the past three years in advancing our novel liver-focused cell and gene therapy platforms, and we are about to enter a new phase as we work toward bringing our first allogeneic cell therapy product to the clinic,” said Jeffrey Tong, Ph.D., Chairman of the Board. “Ambys is pioneering a new approach to treating liver disease with tremendous potential. As we work to bring treatments to patients, Ron’s proven ability to drive results in complex new areas of high innovation, his leadership experience in drug development across the life cycle, and his personal experience having treated patients with severe liver disease will be a tremendous asset.”

“I treated many patients with severe liver disease during my time as a physician, and I have always been struck by how terrible this disease is for both patients and their family members. It has been very difficult to advance new therapies for severe liver disease, and limited progress has been made since I treated these patients over 20 years ago. I am incredibly excited about the cutting-edge approach that Ambys is now taking, and I am inspired by its potential to revolutionize the way patients with severe liver disease are treated. I am also very impressed by the talented Ambys team, and I look forward to leading them to try to make a difference in the lives of millions of patients and their family members impacted by this disease,” said Dr. Park.

About Ambys Medicines

Ambys Medicines is a cell and gene therapy company focused on discovering and developing regenerative and restorative therapies for patients with advanced liver disease. Ambys is pioneering the application of cell and gene therapy to meet the urgent need for novel treatments for those suffering from severe acute and chronic liver diseases. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals and is headquartered in South San Francisco, California. Visit us at ambys.com and follow us on Twitter, LinkedIn, and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210601005158/en/